{"disease":{"id":"refractory-generalized-myasthenia-gravis","name":"Refractory generalized myasthenia gravis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"eculizumab","indication_name":"Refractory generalized myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"H5G1.1","generic_name":"ECULIZUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"C5","drug_class":"Complement Inhibitor [EPC]","quality_score":56,"revenue":null,"mechanism":"Eculizumab-aeeb binds to complement protein C5, inhibiting its cleavage and preventing terminal complement complex formation."},{"drug_id":"soliris","indication_name":"Refractory generalized myasthenia gravis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Soliris","company_name":"Apellis Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02301624","title":"Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT06419166","title":"An Exploratory Clinical Study of GC012F Injection for Refractory gMG","phase":"EARLY_PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Zhejiang University","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}